| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6825725 | Schizophrenia Research | 2013 | 7 Pages |
Abstract
In the absence of such studies it is risky to assume that patients are not at risk of significant distress and long-term harm, and therefore it is difficult to justify the ongoing use of placebo in relapse-prevention RCTs in schizophrenia.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Robin Emsley, Wolfgang W. Fleischhacker,